Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.
Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.
复制标题
Capivasertib 限制 SARS-CoV-2 细胞进入：COVID-19 的潜在临床应用
DOI：
10.7150/ijbs.57810
复制
发表时间：
2021
影响因子：
9.2
通讯作者：
Xie Y
中科院分区：
文献类型：
--
作者：
Sun F;Mu C;Kwok HF;Xu J;Wu Y;Liu W;Sabatier JM;Annweiler C;Li X;Cao Z;Xie Y
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic era.
登录
查看更多内容
GEPIA：用于癌症和正常基因表达谱和交互式分析的网络服务器。
影响因子：
14.9
作者：
Tang Z;Li C;Kang B;Gao G;Li C;Zhang Z
通讯作者：
Zhang Z
DOI：
10.1016/j.bbrc.2009.03.063
发表时间：
2009-05-08
影响因子：
3.1
作者：
Ikonomov, Ognian C.;Sbrissa, Diego;Shisheva, Assia
通讯作者：
Shisheva, Assia
GenCLiP 3：基于共现和自然语言处理，从 PubMed 挖掘人类基因的功能和调控网络。
影响因子：
5.8
作者：
Wang, Jia-Hong;Zhao, Ling-Feng;Huang, Zhong-Xi
通讯作者：
Huang, Zhong-Xi
DOI：
10.1016/j.dsx.2020.04.020
发表时间：
2020-07-01
影响因子：
10
作者：
Astuti, Indwiani;Ysrafil
通讯作者：
Ysrafil
影响因子：
28.2
作者：
Yap TA;Kristeleit R;Michalarea V;Pettitt SJ;Lim JSJ;Carreira S;Roda D;Miller R;Riisnaes R;Miranda S;Figueiredo I;Rodrigues DN;Ward S;Matthews R;Parmar M;Turner A;Tunariu N;Chopra N;Gevensleben H;Turner NC;Ruddle R;Raynaud FI;Decordova S;Swales KE;Finneran L;Hall E;Rugman P;Lindemann JPO;Foxley A;Lord CJ;Banerji U;Plummer R;Basu B;Lopez JS;Drew Y;de Bono JS
通讯作者：
de Bono JS